EDAP TMS S.A. ( (EDAP) ) has released its Q1 earnings. Here is a breakdown of the information EDAP TMS S.A. presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
EDAP TMS S.A., a global leader in robotic energy-based therapies, specializes in minimally invasive medical devices using ultrasound technology, primarily focusing on prostate cancer treatment with its Focal One® system. In the first quarter of 2025, EDAP TMS reported a record number of Focal One system placements, marking a significant milestone for the company. The company also launched the new Focal One i Robotic HIFU System and received CE Mark designation for treating deep infiltrating endometriosis. Financially, the company saw a 6.8% increase in HIFU revenue compared to the previous year, although total worldwide revenue decreased by 9.1% due to a strategic focus shift. Despite a net loss of EUR 7.1 million, EDAP TMS remains optimistic about future growth, driven by strong demand for its Focal One platform and positive clinical trial results supporting its use in prostate cancer treatment. Looking ahead, EDAP TMS anticipates continued revenue growth in its core HIFU business, reflecting confidence in the expanding adoption of its innovative medical technologies.